Measles (Rubeola)
Highly Contagious Paramyxoviral Exanthematous Disease
Primary risk age: Unvaccinated infants, young children, and adolescents.
- Urgency
- Severe
- Typical age
- Unvaccinated infants, young children, and adolescents.
- Body system
- Infectious & Parasitic
Typical course: Acute illness resolves in 7 to 10 days; the rash fades in the order it appeared, leaving a brown discoloration and skin peeling.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Highly Contagious Paramyxoviral Exanthematous Disease
Pathophysiology (Development Path)
The virus is transmitted via respiratory droplets and is highly contagious. It infects the respiratory epithelium, spreads to regional lymph nodes, and enters the bloodstream. It causes systemic endothelial inflammation and targets the skin and mucous membranes, triggering a T-cell mediated immune reaction.
Primary Causes & Etiology
Measles virus (a single-stranded RNA paramyxovirus).
2. Symptom Continuum
- Early Onset Signs
High fever (often >39.5°C), accompanied by the "3 Cs": Cough, Coryza (runny nose), and Conjunctivitis (red, watery, photophobic eyes). Koplik Spots: tiny white-blue spots on a red background inside the cheeks appear 1 to 2 days before the rash.
- Progressive Phase
A maculopapular (flat and bumpy) red rash starting on the face and behind the ears, spreading downward (cephalocaudal progression) to the neck, trunk, arms, and legs.
- Severe Indicators
Sustained high fever, respiratory distress (pneumonia), neurological symptoms (seizures, altered consciousness due to encephalitis), and severe diarrhea leading to dehydration.
3. Clinical Verification
Detection of measles-specific IgM antibodies in serum. Confirm viral RNA via PCR throat or nasopharyngeal swab.
4. Care & Elements Plan
Primary Care Treatment Plan
Supportive care: hydration and antipyretics. Administer high-dose Vitamin A immediately upon diagnosis, which significantly reduces complications and mortality.
Home Support Elements
Isolate the child strictly to prevent spreading. Keep the room dimly lit if photophobia is present. Offer cool fluids and monitor breathing closely.
Generic Active Ingredients (No Brands)
- Vitamin A (elemental retinyl palmitate active ingredient given orally to prevent blindness and pneumonia complications)
- Acetaminophen (for fever comfort).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Seek immediate evaluation if your child develops a high fever, cough, and red eyes, or if a rash appears, especially if they are unvaccinated. Go to the ER for shortness of breath or extreme lethargy.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
Strict isolation of infected individuals. Post-exposure prophylaxis with MMR vaccine or immunoglobulin for unvaccinated contacts within 72 hours.
Immunization Context
Prevented almost entirely by the Measles, Mumps, and Rubella (MMR) vaccine series (first dose at 12-15 months, second dose at 4-6 years).
7. Timelines & Outlook
Active Timeline
Acute illness resolves in 7 to 10 days; the rash fades in the order it appeared, leaving a brown discoloration and skin peeling.
Expected Prognosis
Good in well-nourished children. Complications are more common in infants, malnourished children, and immunocompromised patients.
Potential Untreated Complications
Otitis media, bronchopneumonia (most common cause of death), acute encephalitis, and Subacute Sclerosing Panencephalitis (SSPE - a fatal degenerative brain disease presenting years later).
More in Systemic Contagious Viral Exanthems
Moderate Varicella Zoster (Chickenpox)
Acute Alphaherpesviral Vesicular Exanthematous Disease
Unvaccinated preschool and school-aged children.
Moderate Roseola Infantum (Sixth Disease)
Viral Exanthema Subitum
6 Months to 2 Years
Mild Erythema Infectiosum (Fifth Disease)
Parvovirus-Induced Exanthem
4 to 10 Years